55 research outputs found

    Partial symmetry breaking and heteroclinic tangencies

    Full text link
    We study some global aspects of the bifurcation of an equivariant family of volume-contracting vector fields on the three-dimensional sphere. When part of the symmetry is broken, the vector fields exhibit Bykov cycles. Close to the symmetry, we investigate the mechanism of the emergence of heteroclinic tangencies coexisting with transverse connections. We find persistent suspended horseshoes accompanied by attracting periodic trajectories with long periods

    On Global Bifurcations of Three-dimensional Diffeomorphisms Leading to Lorenz-like Attractors

    No full text
    We study dynamics and bifurcations of three-dimensional diffeomorphisms with nontransversal heteroclinic cycles. We show that bifurcations under consideration lead to the birth of Lorenz-like attractors. They can be viewed as attractors in the Poincare map for periodically perturbed classical Lorenz attractors and hence they can allow for the existence of homoclinic tangencies and wild hyperbolic sets

    Оptimization approach to the synthesis of plasma stabilization system in tokamak ITER

    No full text
    Synthesis of the controller of ITER plasma stabilization system is considered. Stabilization system is based on tokamak diagnostic measurements, defines the voltages in tokamak coils and has the filtering properties. Known methods of synthesis of plasma regulators are advanced by the presented optimization approach. It makes possible to meet the requirements for the dynamics of the stabilization process when considering a set of some arbitrary plasma drops and disturbances. The proposed approach evaluates the ensemble of transient processes of the closed object. Based on this estimations it is possible to use wide range of optimization techniques.Π ΠΎΠ·Π³Π»ΡΠ΄Π°Ρ”Ρ‚ΡŒΡΡ синтСз рСгулятора для систСми стабілізації ΠΏΠ»Π°Π·ΠΌΠΈ Π² Ρ‚ΠΎΠΊΠ°ΠΌΠ°Ρ†Ρ– Π†Π’Π•Π . БистСма стабілізації заснована Π½Π° Π²ΠΈΠΌΡ–Ρ€Π°Ρ… діагностичної систСми Ρ‚ΠΎΠΊΠ°ΠΌΠ°ΠΊΠ°, Π²ΠΎΠ½Π° Π·Π°Π΄Π°Ρ” Π½Π°ΠΏΡ€ΡƒΠ³ΠΈ Π² ΠΊΠ΅Ρ€ΡƒΡŽΡ‡ΠΈΡ… ΠΊΠΎΡ‚ΡƒΡˆΠΊΠ°Ρ… Ρ– ΠΌΠ°Ρ” властивості Ρ„Ρ–Π»ΡŒΡ‚Ρ€Π°Ρ†Ρ–Ρ—. Π’Ρ–Π΄ΠΎΠΌΡ– ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈ синтСзу рСгуляторів ΠΏΠ»Π°Π·ΠΌΠΈ вдосконалСні Π·Π°ΠΏΡ€ΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½ΠΈΠΌ ΠΎΠΏΡ‚ΠΈΠΌΡ–Π·Π°Ρ†Ρ–ΠΉΠ½ΠΈΠΌ ΠΏΡ–Π΄Ρ…ΠΎΠ΄ΠΎΠΌ. Π¦Π΅ Π΄Π°Ρ” ΠΌΠΎΠΆΠ»ΠΈΠ²Ρ–ΡΡ‚ΡŒ Π·Π°Π΄ΠΎΠ²ΠΎΠ»ΡŒΠ½ΠΈΡ‚ΠΈ Π²ΠΈΠΌΠΎΠ³ΠΈ Π΄ΠΎ якості Π΄ΠΈΠ½Π°ΠΌΡ–ΠΊΠΈ процСсу стабілізації Π· урахуванням Ρ€Ρ–Π·Π½ΠΈΡ… нСвизначСностСй Π² Π΄ΠΈΠ½Π°ΠΌΡ–Ρ†Ρ– ΠΏΠ»Π°Π·ΠΌΠΈ, Π² Ρ‚ΠΎΠΌΡƒ числі Π·Π±ΡƒΡ€Π΅Π½ΡŒ ΠΏΠ»Π°Π·ΠΌΠΈ. Π—Π°ΠΏΡ€ΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΡ–Π΄Ρ…Ρ–Π΄ ΠΎΡ†Ρ–Π½ΡŽΡ” ансамбль ΠΏΠ΅Ρ€Π΅Ρ…Ρ–Π΄Π½ΠΈΡ… процСсів Π·Π°ΠΌΠΊΠ½ΡƒΡ‚ΠΎΠ³ΠΎ ΠΎΠ±'Ρ”ΠΊΡ‚Π°. На основі Π·Π°ΠΏΡ€ΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½ΠΈΡ… ΠΎΡ†Ρ–Π½ΠΎΠΊ ΠΌΠΎΠΆΠ½Π° використовувати ΡˆΠΈΡ€ΠΎΠΊΠΈΠΉ спСктр ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ–Π² ΠΎΠΏΡ‚ΠΈΠΌΡ–Π·Π°Ρ†Ρ–Ρ—.РассматриваСтся синтСз рСгулятора для систСмы стабилизации ΠΏΠ»Π°Π·ΠΌΡ‹ Π² Ρ‚ΠΎΠΊΠ°ΠΌΠ°ΠΊΠ΅ ИВЭР. БистСма стабилизации основана Π½Π° измСрСниях диагностичСской систСмы Ρ‚ΠΎΠΊΠ°ΠΌΠ°ΠΊΠ°, ΠΎΠ½Π° Π·Π°Π΄Π°Ρ‘Ρ‚ напряТСния Π² ΡƒΠΏΡ€Π°Π²Π»ΡΡŽΡ‰ΠΈΡ… ΠΊΠ°Ρ‚ΡƒΡˆΠΊΠ°Ρ… ΠΈ ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ‚ свойствами Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ†ΠΈΠΈ. Π˜Π·Π²Π΅ΡΡ‚Π½Ρ‹Π΅ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ синтСза рСгуляторов ΠΏΠ»Π°Π·ΠΌΡ‹ ΡƒΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½Ρ‹ ΠΏΡ€Π΅Π΄Π»Π°Π³Π°Π΅ΠΌΡ‹ΠΌ ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΠΎΠ½Π½Ρ‹ΠΌ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ΠΎΠΌ. Π­Ρ‚ΠΎ Π΄Π°Π΅Ρ‚ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ ΡƒΠ΄ΠΎΠ²Π»Π΅Ρ‚Π²ΠΎΡ€ΠΈΡ‚ΡŒ трСбования ΠΊ качСству Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ процСсса стабилизации с ΡƒΡ‡Ρ‘Ρ‚ΠΎΠΌ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… нСопрСдСлённостСй Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΠΏΠ»Π°Π·ΠΌΡ‹, Π² Ρ‚ΠΎΠΌ числС Π²ΠΎΠ·ΠΌΡƒΡ‰Π΅Π½ΠΈΠΉ ΠΏΠ»Π°Π·ΠΌΡ‹. ΠŸΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹ΠΉ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π΅Ρ‚ ансамбль ΠΏΠ΅Ρ€Π΅Ρ…ΠΎΠ΄Π½Ρ‹Ρ… процСссов Π·Π°ΠΌΠΊΠ½ΡƒΡ‚ΠΎΠ³ΠΎ ΠΎΠ±ΡŠΠ΅ΠΊΡ‚Π°. На основС ΠΏΡ€Π΅Π΄Π»ΠΎΠΆΠ΅Π½Π½Ρ‹Ρ… ΠΎΡ†Π΅Π½ΠΎΠΊ ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ ΡˆΠΈΡ€ΠΎΠΊΠΈΠΉ спСктр ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΠΈ

    Microbiological oropharyngeal patterns in patients with different phenotypes of chronic obstructive pulmonary disease

    No full text
    Persistent bronchial inflammation in chronic obstructive pulmonary disease (COPD) is considered the cause of ventilation disorders and related contamination with conditionally pathogenic microorganisms; the latter can proceed and transform into a full infection, which can aggravate and exacerbate COPD. The aim of the study was to evaluate the relations between the oropharyngeal microbiota in patients with COPD and the clinical, functional, and prognostic parameters of the disease. Materials and Methods. 64 patients with COPD were included in the study; the participants were scheduled to visit our clinic on two occasions. In the first visit, their medical history was studied in detail and the major examination procedures were conducted. Those included an assessment of the respiratory function, the 6-minute walk test, the degree of dyspnea by the Medical Research Council scale, body plethysmography, the diffusion capacity of the lungs, and a chest CT scan. The second visit took place 12 months after the first one to assess the changes in the course of the disease. The result was considered negative if, in the second examination, the patientβ€˜s condition was found more severe. Oropharyngeal samples of all patients were sequenced to identify the V3–V4 variable sites of the 16S rRNA gene. Results. It is found that the microbiological oropharyngeal patterns in COPD patients depend on the source of micro-aspiration. In addition, the changes in the oropharyngeal microbiota correlate with the severity and prognosis of the disease, as well as the patient phenotype. Based on the data obtained by sequencing parts of the 16S rRNA gene, the role of oropharyngeal microbiota in determining the course and prognosis of COPD has been elucidated. Conclusion. The presented clinical and functional characteristics associated with oropharyngeal microbiota indicate that microaspirations from other body compartments not only affect the composition of oropharyngeal microbiota in patients with COPD but also have an important prognostic significance. Β© 2018, Nizhny Novgorod State Medical Academy. All rights reserved

    Microbiological oropharyngeal patterns in patients with different phenotypes of chronic obstructive pulmonary disease

    No full text
    Persistent bronchial inflammation in chronic obstructive pulmonary disease (COPD) is considered the cause of ventilation disorders and related contamination with conditionally pathogenic microorganisms; the latter can proceed and transform into a full infection, which can aggravate and exacerbate COPD. The aim of the study was to evaluate the relations between the oropharyngeal microbiota in patients with COPD and the clinical, functional, and prognostic parameters of the disease. Materials and Methods. 64 patients with COPD were included in the study; the participants were scheduled to visit our clinic on two occasions. In the first visit, their medical history was studied in detail and the major examination procedures were conducted. Those included an assessment of the respiratory function, the 6-minute walk test, the degree of dyspnea by the Medical Research Council scale, body plethysmography, the diffusion capacity of the lungs, and a chest CT scan. The second visit took place 12 months after the first one to assess the changes in the course of the disease. The result was considered negative if, in the second examination, the patientβ€˜s condition was found more severe. Oropharyngeal samples of all patients were sequenced to identify the V3–V4 variable sites of the 16S rRNA gene. Results. It is found that the microbiological oropharyngeal patterns in COPD patients depend on the source of micro-aspiration. In addition, the changes in the oropharyngeal microbiota correlate with the severity and prognosis of the disease, as well as the patient phenotype. Based on the data obtained by sequencing parts of the 16S rRNA gene, the role of oropharyngeal microbiota in determining the course and prognosis of COPD has been elucidated. Conclusion. The presented clinical and functional characteristics associated with oropharyngeal microbiota indicate that microaspirations from other body compartments not only affect the composition of oropharyngeal microbiota in patients with COPD but also have an important prognostic significance. Β© 2018, Nizhny Novgorod State Medical Academy. All rights reserved

    Periostin as a biomarker of allergic inflammation in atopic bronchial asthma and allergic rhinitis (A pilot study)

    No full text
    Β© 2020, Privolzhsky Research Medical University. All rights reserved. The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation of AR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg β€” with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies

    Periostin as a biomarker of allergic inflammation in atopic bronchial asthma and allergic rhinitis (A pilot study)

    No full text
    The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR. Materials and Methods. In 43 patients aged 4–17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay. Results. Exacerbation of AR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg β€” with hypertrophy of the NM in the medial surface of the concha; p=0.02. Conclusion. Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies. Β© 2020, Privolzhsky Research Medical University. All rights reserved

    Extracellular matrix markers and methods for their study

    No full text
    The extracellular matrix (ECM) is a complex meshwork consisting mainly of proteins and carbohydrates; it is currently viewed as a key factor of tissue organization and homeostasis. In each organ, the composition of ECM is different: It includes a variety of fibrillar components, such as collagens, fibronectin, and elastin, as well as non-fibrillar molecules: Proteoglycans, hyaluronan, glycoproteins, and matrix proteins. ECM is an active tissue, where the de novo syntheses of structural components are constantly taking place. In parallel, ECM components undergo degradation catalyzed by a number of enzymes including matrix metalloproteinases. The synthesis and degradation of ECM components are controlled by mediators and cytokines, metabolic, epigenetic, and environmental factors. Currently, a large amount of evidence indicates that modifications (remodeling) of ECM play an important role in the pathogenesis of clinical conditions. This may explain the increasing interest in the markers of ECM remodeling both in health and disease. In recent years, many of the ECM markers were considered targets for diagnosing, predicting, and treating diseases. In this review, we discuss some of the currently known ECM markers and methods used for their determination. Β© 2019, Privolzhsky Research Medical University. All rights reserved

    ΠœΠ°Ρ€ΠΊΠ΅Ρ€Ρ‹ состояния ΡΠΊΡΡ‚Ρ€Π°Ρ†Π΅Π»Π»ΡŽΠ»ΡΡ€Π½ΠΎΠ³ΠΎ матрикса ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ ΠΈΡ… исслСдования (ΠΎΠ±Π·ΠΎΡ€)

    No full text
    The extracellular matrix (ECM) is a complex meshwork consisting mainly of proteins and carbohydrates; it is currently viewed as a key factor of tissue organization and homeostasis. In each organ, the composition of ECM is different: it includes a variety of fibrillar components, such as collagens, fibronectin, and elastin, as well as non-fibrillar molecules: proteoglycans, hyaluronan, glycoproteins, and matrix proteins. ECM is an active tissue, where the de novo syntheses of structural components are constantly taking place. In parallel, ECM components undergo degradation catalyzed by a number of enzymes including matrix metalloproteinases. The synthesis and degradation of ECM components are controlled by mediators and cytokines, metabolic, epigenetic, and environmental factors. Currently, a large amount of evidence indicates that modifications (remodeling) of ECM play an important role in the pathogenesis of clinical conditions. This may explain the increasing interest in the markers of ECM remodeling both in health and disease. In recent years, many of the ECM markers were considered targets for diagnosing, predicting, and treating diseases. In this review, we discuss some of the currently known ECM markers and methods used for their determination.Π­ΠΊΡΡ‚Ρ€Π°Ρ†Π΅Π»Π»ΡŽΠ»ΡΡ€Π½Ρ‹ΠΉ (Π²Π½Π΅ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹ΠΉ) матрикс (ЭЦМ) прСдставляСт собой ΡΠ»ΠΎΠΆΠ½ΡƒΡŽ ΡΠ΅Ρ‚Ρ‡Π°Ρ‚ΡƒΡŽ структуру, ΡΠΎΡΡ‚ΠΎΡΡ‰ΡƒΡŽ прСимущСствСнно ΠΈΠ· Π±Π΅Π»ΠΊΠΎΠ² ΠΈ ΡƒΠ³Π»Π΅Π²ΠΎΠ΄ΠΎΠ², ΠΈ рассматриваСтся Π² настоящСС врСмя ΠΊΠ°ΠΊ ΠΊΠ»ΡŽΡ‡Π΅Π²ΠΎΠΉ рСгулятор ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ†ΠΈΠΈ Ρ‚ΠΊΠ°Π½Π΅ΠΉ ΠΈ гомСостаза. Π’ ΠΊΠ°ΠΆΠ΄ΠΎΠΌ ΠΎΡ€Π³Π°Π½Π΅ состав ЭЦМ Ρ€Π°Π·Π»ΠΈΡ‡Π΅Π½, Π²ΠΊΠ»ΡŽΡ‡Π°Π΅Ρ‚ Ρ€Π°Π·Π½ΠΎΠΎΠ±Ρ€Π°Π·Π½Ρ‹Π΅ фибриллярныС ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚Ρ‹, Ρ‚Π°ΠΊΠΈΠ΅ ΠΊΠ°ΠΊ ΠΊΠΎΠ»Π»Π°Π³Π΅Π½Ρ‹, Ρ„ΠΈΠ±Ρ€ΠΎΠ½Π΅ΠΊΡ‚ΠΈΠ½ ΠΈ эластин, ΠΈ нСфибриллярныС ΠΌΠΎΠ»Π΅ΠΊΡƒΠ»Ρ‹ - ΠΏΡ€ΠΎΡ‚Π΅ΠΎΠ³Π»ΠΈΠΊΠ°Π½Ρ‹, Π³ΠΈΠ°Π»ΡƒΡ€ΠΎΠ½Π°Π½ ΠΈ Π³Π»ΠΈΠΊΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ½Ρ‹, матриксныС Π±Π΅Π»ΠΊΠΈ. ЭЦМ являСтся Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΠΉ структурой, Π² ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠΉ постоянно происходят процСссы синтСза de novo структурных ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² ΠΈ ΠΏΠ°Ρ€Π°Π»Π»Π΅Π»ΡŒΠ½ΠΎ - ΠΈΡ… Π΄Π΅Π³Ρ€Π°Π΄Π°Ρ†ΠΈΠΈ, осущСствляСмой прСимущСствСнно с участиСм Ρ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚ΠΎΠ², Π² Ρ‚ΠΎΠΌ числС матриксных ΠΌΠ΅Ρ‚Π°Π»Π»ΠΎΠΏΡ€ΠΎΡ‚Π΅ΠΈΠ½Π°Π·. Π‘ΠΈΠ½Ρ‚Π΅Π· ΠΈ дСградация ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ² матрикса находятся ΠΏΠΎΠ΄ слоТным рСгуляторным влияниСм Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… ΠΌΠ΅Π΄ΠΈΠ°Ρ‚ΠΎΡ€ΠΎΠ² ΠΈ Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½ΠΎΠ², мСтаболичСских, эпигСнСтичСских ΠΈ срСдовых воздСйствий. Π’ настоящСС врСмя Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΎ большоС количСство Π΄ΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΡŒΡΡ‚Π², Ρ‡Ρ‚ΠΎ измСнСния ЭЦМ ΠΈΠ³Ρ€Π°ΡŽΡ‚ Π²Π°ΠΆΠ½ΡƒΡŽ Ρ€ΠΎΠ»ΡŒ ΠΏΡ€ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… патологичСских состояниях. Π­Ρ‚ΠΈΠΌ обусловлСн интСрСс ΠΊ поиску ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ΠΎΠ², ΠΎΡ‚Ρ€Π°ΠΆΠ°ΡŽΡ‰ΠΈΡ… состояниС ЭЦМ Π² Ρ€Π°Π·Π½Ρ‹Ρ… ΠΎΡ€Π³Π°Π½Π°Ρ… ΠΈ тканях ΠΊΠ°ΠΊ Π² физиологичСских условиях, Ρ‚Π°ΠΊ ΠΈ ΠΏΡ€ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Π°Ρ… ΠΏΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π’ послСдниС Π³ΠΎΠ΄Ρ‹ ΠΌΠ½ΠΎΠ³ΠΈΠ΅ ΠΈΠ· ΠΌΠΎΠ»Π΅ΠΊΡƒΠ» ЭЦМ Ρ€Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°ΡŽΡ‚ΡΡ Π² качСствС мишСнСй для диагностики, прогнозирования ΠΈ лСчСния Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π’ Π΄Π°Π½Π½ΠΎΠΌ ΠΎΠ±Π·ΠΎΡ€Π΅ ΠΌΡ‹ систСматизировали основныС описанныС Π² настоящий ΠΌΠΎΠΌΠ΅Π½Ρ‚ ΠΌΠ°Ρ€ΠΊΠ΅Ρ€Ρ‹ состояния ЭЦМ ΠΈ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Π΅ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹ ΠΈΡ… опрСдСлСния
    • …
    corecore